Nalbuphine ER

A press release

Trevi Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference

March 21, 2018

New Haven, CT, March 21, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage clinical development company focused on developing Nalbuphine® […]

A press release

Trevi Therapeutics Hires Dr. Helena Brett-Smith as Chief Development Officer

October 12, 2017

Highly experienced clinical drug developer to oversee R&D functions and Company’s Phase 3 development program New Haven, CT, October 12,

A press release

Trevi Therapeutics Raises $50 Million Series C Financing Led by New Enterprise Associates

July 20, 2017

Company continuing the development of Nalbuphine® ER in chronic pruritus conditions New Haven, CT, July 20, 2017 – Trevi Therapeutics,